The company is on track to file an IND for KB407 in 2021PITTSBURGH, Aug. 17, 2020 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that the U.S. Food
more on finance.yahoo.com